Fecal calprotectin in inflammatory bowel disease

: Inflammatory bowel disease (IBD) and irritable bowel syndrome share many symptoms. While irritable bowel syndrome is a functional bowel disorder for which no specific treatment is available, the range of effective therapies for IBD is evolving rapidly. Accurate diagnosis of IBD is therefore essential. Clinical assessment, together with various imaging modalities and endoscopy, has been the mainstay of diagnosis for many years. Fecal biomarkers of gastrointestinal inflammation have appeared in the past decade, of which calprotectin, a neutrophil cytosolic protein, has been studied the most. Crohn’s disease and ulcerative colitis are chronic remitting and relapsing diseases, and objective assessment of disease activity and response to treatment are important. This review focuses on the use of fecal calprotectin measurements in the diagnosis and of patients with

[1]  R. Sherwood,et al.  Fecal calprotectin in inflammatory bowel disease , 2016, Clinical and experimental gastroenterology.

[2]  Steven J Brown,et al.  Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. , 2015, Gastroenterology.

[3]  E. Cabré,et al.  High Within-day Variability of Fecal Calprotectin Levels in Patients with Active Ulcerative Colitis: What Is the Best Timing for Stool Sampling? , 2015, Inflammatory bowel diseases.

[4]  E. Cotte,et al.  Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn’s Disease , 2015, The American Journal of Gastroenterology.

[5]  David C. Wilson,et al.  Faecal Calprotectin in Suspected Paediatric Inflammatory Bowel Disease , 2015, Journal of pediatric gastroenterology and nutrition.

[6]  Takayuki Yamamoto The clinical value of faecal calprotectin and lactoferrin measurement in postoperative Crohn’s disease , 2015, United European gastroenterology journal.

[7]  C. Beglinger,et al.  Fecal Calprotectin and the Clinical Activity Index Are Both Useful to Monitor Medical Treatment in Patients with Ulcerative Colitis , 2015, Digestive Diseases and Sciences.

[8]  Christoph Beglinger,et al.  The role and utility of faecal markers in inflammatory bowel disease , 2015, Therapeutic advances in gastroenterology.

[9]  G. Rogler,et al.  Monitoring Disease Activity and Progression in Crohn's Disease. A Swiss Perspective on the IBD Ahead ‘Optimised Monitoring' Recommendations , 2014, Digestion.

[10]  A. Ristimäki,et al.  Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? , 2014, Journal of Crohn's & colitis.

[11]  L. Öhman,et al.  The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. , 2014, Journal of Crohn's & colitis.

[12]  P. Henderson,et al.  The Diagnostic Accuracy of Fecal Calprotectin During the Investigation of Suspected Pediatric Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis , 2014, The American Journal of Gastroenterology.

[13]  C. Beglinger,et al.  Diagnostic yield of endoscopy in patients with abdominal complaints: incremental value of faecal calprotectin on guidelines of appropriateness , 2014, BMC Gastroenterology.

[14]  M. Kiszka-Kanowitz,et al.  The correlation between fecal calprotectin, simple clinical colitis activity index and biochemical markers in ulcerative colitis during high-dose steroid treatment , 2014, Scandinavian journal of gastroenterology.

[15]  G. D'Haens,et al.  Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease , 2014, United European gastroenterology journal.

[16]  T. Lobaton,et al.  A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. , 2013, Journal of Crohn's & colitis.

[17]  J. Belaiche,et al.  Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy , 2013, Inflammatory bowel diseases.

[18]  P. Pavlidis,et al.  Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care , 2013, Scandinavian journal of gastroenterology.

[19]  Takayuki Yamamoto,et al.  Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn’s disease after ileocolonic resection: A prospective pilot study , 2013, United European gastroenterology journal.

[20]  H. Nielsen,et al.  Evaluation of fecal calprotectin in Campylobacter concisus and Campylobacter jejuni/coli gastroenteritis , 2013, Scandinavian journal of gastroenterology.

[21]  A. Schoepfer,et al.  Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood Leukocytes , 2013, Inflammatory bowel diseases.

[22]  A. Morris,et al.  A prospective single‐centre evaluation of the intra‐individual variability of faecal calprotectin in quiescent Crohn's disease , 2013, Alimentary pharmacology & therapeutics.

[23]  R. Gama,et al.  Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits , 2013, Annals of clinical biochemistry.

[24]  S. Vermeire,et al.  Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease , 2012, Inflammatory bowel diseases.

[25]  Jing-Long Huang,et al.  Fecal Calprotectin as a Correlative Marker in Clinical Severity of Infectious Diarrhea and Usefulness in Evaluating Bacterial or Viral Pathogens in Children , 2012, Journal of pediatric gastroenterology and nutrition.

[26]  M. Färkkilä,et al.  Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF&agr; blocking agents , 2012, Inflammatory bowel diseases.

[27]  R. Sherwood,et al.  Faecal markers of gastrointestinal inflammation , 2012, Journal of Clinical Pathology.

[28]  O. Dewit,et al.  Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. , 2012, Journal of Crohn's & colitis.

[29]  N. D. de Wit,et al.  Diagnostic accuracy of point-of-care fecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: the Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary Care (CEDAR) study. , 2012, Clinical chemistry.

[30]  A. Schoepfer,et al.  Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. , 2012, Journal of Crohn's & colitis.

[31]  M. Huml,et al.  Evaluation of faecal calprotectin as a valuable non‐invasive marker in distinguishing gut pathogens in young children with acute gastroenteritis , 2010, Acta paediatrica.

[32]  P. V. van Rheenen,et al.  Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis , 2010, BMJ : British Medical Journal.

[33]  K. Kolho,et al.  Faecal calprotectin in children with clinically quiescent inflammatory bowel disease , 2010, Scandinavian journal of gastroenterology.

[34]  J. Gisbert,et al.  Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? , 2010, Journal of Crohn's & colitis.

[35]  M. Pakarinen,et al.  Fecal calprotectin mirrors inflammation of the distal ileum and bowel function after restorative proctocolectomy for pediatric‐onset ulcerative colitis† , 2010, Inflammatory bowel diseases.

[36]  I. Ayadi,et al.  Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study , 2010, European journal of gastroenterology & hepatology.

[37]  H. Tilg,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. , 2010, Journal of Crohn's & colitis.

[38]  C. Geczy,et al.  ANTI-INFECTIVE PROTECTIVE PROPERTIES OF S100 CALGRANULINS. , 2009, Anti-inflammatory & anti-allergy agents in medicinal chemistry.

[39]  J. Mate,et al.  Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse , 2009, Inflammatory bowel diseases.

[40]  M. Mohiuddin,et al.  Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease , 2009, The British journal of surgery.

[41]  H. Drummond,et al.  Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative Colitis , 2009, The American Journal of Gastroenterology.

[42]  L. Maiden Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy , 2009, Journal of Gastroenterology.

[43]  M. Färkkilä,et al.  Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease , 2008, Inflammatory bowel diseases.

[44]  M. Castro,et al.  Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases , 2008, Inflammatory bowel diseases.

[45]  R. D'Incà,et al.  Can Calprotectin Predict Relapse Risk in Inflammatory Bowel Disease? , 2008, The American Journal of Gastroenterology.

[46]  S. Kugathasan,et al.  Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease , 2008, Inflammatory bowel diseases.

[47]  A. Forbes,et al.  Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis , 2008, European journal of gastroenterology & hepatology.

[48]  A. Michalsen,et al.  Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices , 2008, The American Journal of Gastroenterology.

[49]  M. Färkkilä,et al.  Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings , 2008, Inflammatory bowel diseases.

[50]  A. Darzi,et al.  Diagnostic Precision of Fecal Calprotectin for Inflammatory Bowel Disease and Colorectal Malignancy , 2007, The American Journal of Gastroenterology.

[51]  R. D'Incà,et al.  Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: A multicenter prospective study. , 2006, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[52]  T. Raivio,et al.  Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease , 2006, Scandinavian journal of gastroenterology.

[53]  M. Bottai,et al.  Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease , 2005, Gut.

[54]  M. Vatn,et al.  Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT) , 2004, Gut.

[55]  I. Forgacs,et al.  Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. , 2002, Gastroenterology.

[56]  M. Fagerhol,et al.  Age-dependent variations in fecal calprotectin concentrations in children. , 2002, Journal of pediatric gastroenterology and nutrition.

[57]  I. Bjarnason,et al.  Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma , 2001, Gut.

[58]  E. Husebye,et al.  Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm , 2001, American Journal of Gastroenterology.

[59]  I. Bjarnason,et al.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. , 2000, Gastroenterology.

[60]  A. Price,et al.  Assessment of ileal pouch inflammation by single-stool calprotectin assay , 2000, Diseases of the colon and rectum.

[61]  A. Røseth,et al.  High prevalence of NSAID enteropathy as shown by a simple faecal test , 1999, Gut.

[62]  Clinique La Source-Baulieu Monitoring Disease Activity and Progression in Crohn's Disease. A Swiss Perspective on the IBD Ahead 'Optimised Monitoring' Recommendations , 2016 .

[63]  Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel , 2012 .

[64]  M. Picco Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI , 2010 .

[65]  J. Gisbert,et al.  Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[66]  F. Castiglione,et al.  The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound. , 2006, European review for medical and pharmacological sciences.

[67]  A. Røseth,et al.  Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. , 1999, Scandinavian journal of gastroenterology.

[68]  J. Jahnsen,et al.  Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. , 1997, Digestion.

[69]  I. Dale,et al.  A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. , 1980, Bulletin europeen de physiopathologie respiratoire.

[70]  G PLACITELLI,et al.  [Ulcerative colitis]. , 1958, La Riforma medica.